China independent clinical laboratory industry report, 2016 2020

China Independent Clinical Laboratory

Industry Report, 2016-2020

Sep. 2016

METHODOLOGY

Both primary and secondary research methodologies were used

in preparing this study. Initially, a comprehensive and exhaustive

search of the literature on this industry was conducted. These

sources included related books and journals, trade literature,

marketing literature, other product/promotional literature, annual

reports, security analyst reports, and other publications.

Subsequently, telephone interviews or email correspondence

was conducted with marketing executives etc. Other sources

included related magazines, academics, and consulting

companies.

INFORMATION SOURCES

The primary information sources include Company Reports,

and National Bureau of Statistics of China etc.

STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant

competitor information, analysis, insight and projection on the

competitive pattern and key companies in the industry, crucial to the

development and implementation of effective business, marketing and

R&D programs.

REPORT OBJECTIVES To establish a comprehensive, factual, annually updated and cost-

effective information base on market size, competition patterns,

market segments, goals and strategies of the leading players in the

market, reviews and forecasts.

To assist potential market entrants in evaluating prospective

acquisition and joint venture candidates.

To complement the organizations’ internal competitor information

gathering efforts with strategic analysis, data interpretation and

insight.

To suggest for concerned investors in line with the current

development of this industry as well as the development tendency.

To help company to succeed in a competitive market, and

understand the size and growth rate of any opportunity.

Room 509, Building 1+1, No.10, Caihefang Road, Haidian District, Beijing, 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● [email protected]

Copyright 2012 ResearchInChina

AbstractOwing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of

health care reform, the Chinese independent clinical laboratory market size has been growing radically in recent years, reaching about RMB6.5 billion with a year-on-year increase of 37.4% in 2015; it is expected to grow rapidly at a rate of 30%-40% over the next three to five years and report RMB29.2 billion in 2020.

There are approximately200 independent clinical laboratory enterprises in China, mainly comprehensive diagnostic chains and special diagnostic enterprises. KingMed Diagnostics, Dian Diagnostics, ADICON Clinical Laboratories, and DaAn Health (invested by Da An Gene), which hold a combined market share of 70% and all adopt chain-based model of comprehensive diagnostic services. By the end of 2015, the four enterprises separately had 31, 26, 20 and 8 independent clinical laboratories. While expanding clinical laboratory services actively, all companies are deploying " laboratory +" industrial chain vigorously.

As a titan in China independent clinical laboratory industry, KingMed Diagnostics earned the revenue of RMB2.5 billion to RMB3 billion in 2015 with 40% market share. In the past two years, KingMed Diagnostics has been involved in production and sale of in vitro diagnostic products through acquisitions and independent R & D; moreover, it has made layout on "laboratory + Internet" services by acquiring GoHeath (Guangzhou Jinzhun), access to Tmall’s online pharmacies, etc..

Second to KingMed Diagnostics, Dian Diagnostics gained the revenue of RMB1.079 billion from independent clinical laboratory in 2015. In recent years, the company has implemented the strategy of horizontal expansion, vertical digging, technological innovation and industrial chain integration aggressively. It has arranged the " diagnosis +" ecosystem which refers to the expansion of other related services such as health management, judicial diagnostics, medicine CRO, cold chain logistics and mobile health with a focus on "diagnostic services + products". Since November 2015, the company has acquired Freda,Yuanding, ShengshiKehua, Faith Medical, Kingpe and many other high-quality IVD distributors for over RMB1 billion totally. In 2015, the company launched a new mode for chain expansion of physical examination services -- a health management center (Hangzhou Full-process International Health Medical Management Center Co., Ltd.) established with Hangzhou Jiebai, Baida Group. Meanwhile, Dian Diagnostics signed strategic cooperation agreements with The Johns Hopkins Hospital and AliHealth respectively to explore the "diagnosis + Internet" business mode energetically. At the beginning of 2016, Dian Diagnostics collaborated with Tigermed to set up a joint venture -- Shanghai Teddy Medical Institute Co., Ltd., marking the former’s foray into pharmaceutical CRO.


Copyright 2012ResearchInChina

The third-ranked ADICON Clinical Laboratories which still enjoys superiority in East China has not realized the distribution of nationwide chain operation, but its special laboratory items have showed strong competitiveness. The company is not only authorized by the global pharmaceutical giant Roche to become "Roche’s Demonstration Laboratory in China", but also cooperates with Siemens Healthineers, Japan SRL, South Korea SCL, France Bio Mérieux, etc. in medical diagnostics.

Being bullish about the prospects of the Chinese independent clinical laboratory market, a number of small and medium Chinese independent clinical laboratory companies have drawn or plan to draw support fromthe capital market to further expand the clinical laboratory market. In 2014-mid-2016, Surexam Biotechnology, Shanghai Labway, Beijing Lepu, Shanghai Biotecan, Jiangsu Superbio, Beijing Lawke and other companies went public at NEW OTCBB in China. Wherein, Jiangsu Superbio witnessed the fastest revenue growth in clinical laboratory, namely the year-on-year surge of 161.0% in 2015; Shanghai Biotecan took the second place with the CAGR of 92.1% in 2013-2015. Shanghai Labway Clinical Laboraory obtained the clinical laboratory revenue of RMB127.8 million in 2015, but the revenue growth has slowed down due to the construction and expansion of laboratories in recent years.

China Independent Clinical Laboratory Industry Report, 2016-2020 highlights the followings: Policy environment, international market, development status, and competitive landscape of China’s independent clinical laboratory industry;Upstream and downstream markets of China’s independent clinical laboratory industry and their impacts;Operation, and independent clinical laboratory business of 19 relevant enterprises in China;Development outlook of China’s independent clinical laboratory industry in 2016-2020 and operational comparison among key players.


Copyright 2012ResearchInChina

1. Overview of Independent Clinical Laboratory1.1 Definition1.2 Industry Chain

2. Overview of China Independent Clinical Laboratory Industry

2.1 Policy Environment2.1.1 Access Policy2.1.2 Industry Policy2.2 International Market2.2.1 Status Quo2.2.2 Benchmarking Enterprises2.3 Development2.4 Competitive Landscape

3. Upstream and Downstream Markets of China Independent Clinical Laboratory Industry

3.1 Upstream Market3.1.1 Status Quo3.1.2 Competition Pattern3.2 Downstream Market3.2.1 Independent Clinical Laboratory Market Sees Huge

Capacity3.2.2 Healthcare Reform Boosts the Rapid Development of

Independent Clinical Laboratory Market3.2.3 Demand Diversification Promotes the Upgrading of

Independent Clinical Laboratory Industry

Table of contents


3.2.4 Healthcare Demand Growth Propels the Independent Clinical Laboratory Forward Faster

3.2.5 Internet Will Stimulate the Business Model Upgrade of Independent Clinical Laboratory Industry

4. Key Players4.1 KingMed Diagnostics4.1.1 Profile4.1.2 Operation4.1.3 Revenue Structure4.1.4 Gross Margin4.1.5 R&D and Investment4.1.6 Independent Clinical Laboratory4.1.7 Client and Supplier4.1.8 Forecast and Outlook4.2 ADICON4.2.1 Profile4.2.2 Independent Clinical Laboratory4.2.3 Development4.3 Dian Diagnostics4.3.1 Profile4.3.2 Operation4.3.3 Revenue Structure4.3.4 Gross Margin4.3.5 R&D and Investment4.3.6 Independent Clinical Laboratory4.3.7 Client and Supplier

4.3.8 Forecast and Outlook4.4 DAAN Gene4.4.1 Profile4.4.2 Operation4.4.3 Revenue Structure4.4.4 Gross Margin4.4.5 R&D and Investment4.4.6 Independent Clinical Laboratory4.4.7 Client and Supplier4.4.8 Forecast and Outlook4.5 Shanghai Labway Clinical Laboratory Co., Ltd.4.5.1 Profile4.5.2 Operation4.5.3 Revenue Structure4.5.4 Gross Margin4.5.5 R&D and Investment4.5.6 Independent Clinical Laboratory4.5.7 Client and Supplier4.5.8 Forecast and Outlook4.6 NYMPHAVN Biotechnology4.6.1 Profile4.6.2 Operation4.6.3 Revenue Structure4.6.4 Gross Margin4.6.5 R&D and Investment4.6.6 Independent Clinical Laboratory4.6.7 Forecast and Outlook

4.7 SurExam Bio-Tech Co., Ltd.4.7.1 Profile4.7.2 Operation4.7.3 Revenue Structure4.7.4 Gross Margin4.7.5 R&D and Investment4.7.6 Independent Clinical Laboratory4.7.7 Client and Supplier4.7.8 Forecast and Outlook4.8 Ningbo Medicalsystem Biotechnology Co., Ltd.4.8.1 Profile4.8.2 Operation4.8.3 Revenue Structure4.8.4 Gross Margin4.8.5 R&D and Investment4.8.6 Independent Clinical Laboratory4.8.7 Client and Supplier4.8.8 Forecast and Outlook4.9 Beijing Lawke Health Laboratory Co., Ltd.4.9.1 Profile4.9.2 Operation4.9.3 Revenue Structure4.9.4 Gross Margin4.9.5 Forecast and Outlook4.10 Beijing Lepu Gene Technology Co.,Ltd.4.10.1 Profile4.10.2 Operation

Table of contents


4.10.3 Gross Margin4.10.4 Forecast and Outlook4.11 Shanghai Biotecan Pharmaceuticals Co., Ltd.4.11.1 Profile4.11.2 Operation4.11.3 Revenue Structure4.11.4 Gross Margin4.11.5 Independent Clinical Laboratory4.11.6 Forecast and Outlook4.12 Jiangsu Superbio Life Science Co., Ltd.4.12.1 Profile4.12.2 Operation4.12.3 Revenue Structure4.12.4 Gross Margin4.12.5 Client and Supplier4.12.6 Forecast and Outlook4.13 Other Enterprises4.13.1 Kindstar Global4.13.2 Xiamen Amoy Diagnostics Co., Ltd.4.13.3 CapitalBio Corporation4.13.4 Beijing Adinovo Technologies Co., Ltd.4.13.5 Beijing Deyi Diagnostics Technology Co., Ltd.4.13.6 IPE Biotechnology Co., Ltd.4.13.7 Centre Testing International

5. Forecast and Outlook5.1 Industry Development

5.2 Operation Comparison between Enterprises5.2.1 Revenue5.2.2 Gross Margin

• Independent Clinical Laboratory Industry Chain• Comparison of Independent Clinical Laboratory Undertakers between China and USA• Policies Concerning Independent Clinical Laboratory Industry in China, 2010-2016• Market Share of Independent Clinical Laboratories in Major Countries• U.S. Independent Clinical Laboratory Market Share by Test Item• U.S. Clinical Laboratory Market Share by Demand Side• Revenue and Net Income of Quest, 2009-2016• Revenue of Quest Diagnostics by Business, 2014-2015• Major M&As of Quest Diagnostics, 2006-2015• Revenue and Operating Income of LabCorp, 2010-2016• Revenue Breakdown of LabCorp by Business, 2013-2016• Major M&As of LabCorp, 2007-2015• Market Scale of independent clinical laboratory industry in China,2013-2016• Revenue CAGR of Some Independent Clinical Laboratory Enterprises in China, 2012-2015• Market Share of Major Enterprises in China’s Independent Clinical Laboratory Industry, 2015• Basic Characteristics and Market Share of Major Independent Clinical Laboratory Enterprises in China, 2015• Development History of In Vitro Diagnostic Industry in China• Market Size of In Vitro Diagnostic Industry in China, 2009-2015• Market Structure of In Vitro Diagnostic Reagent Industry in China, 2015• Comparison of Diagnostic Instrument Varieties between Domestic and Foreign Enterprises• Competition Pattern of Diagnostic Reagent Industry in China• IVD Revenue and Market Share of Major Diagnostic Reagent Enterprises in China, 2013-2015• Business Revenue and Inspection Revenue of Public Hospitals in China, 2014• Per Capita Inspection Fees and % of Outpatient Expenses of Outpatients in Chinese Hospitals, 2010-2014• Per Capita Inspection Fees and % of Hospitalization Expenses of Inpatients in Chinese Hospitals, 2010-2014

Selected Charts


• Business Revenue and Inspection Revenue of Public Hospitals in China by Type of Visit, 2014• Medical Services of Health Agencies in China, 2012-2015• Number of Medical Institutions in China, 2012-2015• Health Expenditure and % of GDP in China, 1980-2015• Per Capita Health Expenditure and YoY Growth in China, 2006-2015• Revenue and Net Income of KingMed Diagnostics, 2012-2015• Revenue Breakdown of KingMed Diagnostics by Business, 2012-2015• Revenue Breakdown of KingMed Diagnostics by Region, 2012-2015• Gross Margin of KingMed Diagnostics by Business, 2012-2015• R&D Costs and % of Total Revenue of KingMed Diagnostics, 2012-2015• Proposed Fundraising & Investment Projects and Value of KingMed Diagnostics, 2016 • Distribution of Independent Clinical Laboratories of KingMed Diagnostics, as of June 2016 • Capacity and Output of KingMed Diagnostics (by Business), 2014-2015• Service Prices of KingMed Diagnostics (by Business), 2012-2015• Revenue of Dian Diagnostics from Top 5 Clients and % in Total Revenue, 2012-2015• Revenue of KingMed Diagnostics from Top 5 Clients and % of Total Revenue, 2014-2015• Procurement of KingMed Diagnostics from Top 5 Suppliers and % of Total Procurement, 2014-2015• Revenue and Net Income of KingMed Diagnostics, 2015-2020• Revenue and Net Income of Dian Diagnostics, 2010-2016• Revenue Breakdown of Dian Diagnostics by Product, 2010-2016• Revenue Breakdown of Dian Diagnostics by Region, 2009-2016• Gross Margin of Dian Diagnostics, 2010-2016• Gross Margin of Dian Diagnostics by Product, 2010-2015• R&D Costs and % of Total Revenue of Dian Diagnostics, 2010-2016• Dian Diagnostics’ Revenue from Independent Clinical Laboratory and YoY Growth, 2009-2016• Revenue of Dian Diagnostics’ Top 5 Clients and % in Total Revenue, 2011-2016

Selected Charts


• Revenue of Dian Diagnostics from Top 5 Clients and % of Total Revenue, 2015-2016• Procurement of Dian Diagnostics’ Top 5 Suppliers and % in Total Procurement, 2011-2016• Procurement of Dian Diagnostics’ Top 5 Suppliers and % in Total Procurement, 2015-2016 • Revenue and Net Income of Dian Diagnostics, 2015-2020E• Revenue and Net Income of Da An Gene, 2010-2016• Revenue Breakdown of Da An Gene by Business, 2010-2016• Revenue Breakdown of Da An Gene by Region, 2010-2016• Gross Margin of Da An Gene, 2010-2016• Gross Margin of Da An Gene by Business, 2010-2016• R&D Costs and % of Total Revenue of Da An Gene, 2011-2016• Main Assets and Business of Da An Gene• Industrial Chain Layout of Da An Gene• Medical Resources of Sun Yat-Sen University• Da An Gene’s Revenue from Independent Clinical Laboratory and YoY Growth, 2010-2016• Revenue of Da An Gene from Top 5 Clients and % in Total Revenue, 2014-2015• Top 5 Suppliers of Da An Gene, 2014-2015• Revenue and Net Income of Da An Gene, 2015-2020E• Revenue and Net Income of Shanghai Labway, 2013-2016• Revenue Breakdown of Shanghai Labway by Product, 2013-2016• Gross Margin of Shanghai Labway by Product, 2013-2016• R&D Costs and % of Medical Diagnosis Service’s revenue of Nymphavn Biotechnology, 2013-2016• Revenue from and Gross Margin of Independent Clinical Laboratory Business of Medicalsystem Biotechnology, 2013-2016• Revenue of Shanghai Labway’s Top 5 Clients and % in Total Revenue, 2013-2015• Revenue of Shanghai Labway’s Top 5 Clients and % in Total Revenue, 2015• Procurement of Shanghai Labway’ Top 5 Suppliers and % in Total Procurement, 2013-2015

Selected Charts


• Procurement of Shanghai Labway’ Top 5 Suppliers and % in Total Procurement, 2015• Revenue and Net Income of Nymphavn Biotechnology, 2009-2016• Revenue Breakdown of Nymphavn Biotechnology by Product, 2009-2016• Gross Margin of Nymphavn Biotechnology, 2009-2016• Gross Margin of Nymphavn Biotechnology by Product, 2009-2016• R&D Costs and % of Total Revenue of Nymphavn Biotechnology, 2011-2016• Revenue from and Gross Margin of Independent Clinical Laboratory Business of Nymphavn Biotechnology, 2009-2016• Revenue and Net Income of Nymphavn Biotechnology, 2015-2020E• Subsidiaries and Main Businesses of Surexam Biotechnology• Revenue and Net Income of Surexam Biotechnology, 2011-2016• Revenue Breakdown of Surexam Biotechnology by Business, 2011-2016• Gross Margin of Surexam Biotechnology, 2011-2016• Gross Margin of Surexam Biotechnology by Product, 2009-2016• R&D Costs and % of Total Revenue of Surexam Biotechnology, 2011-2016• Revenue from and Gross Margin of Independent Clinical Laboratory Business of Surexam Biotechnology, 2011-2016• Revenue of Surexam Biotechnology from Top 5 Clients and % of Total Revenue, 2015• Procurement of Surexam Biotechnology from Top 5 Suppliers and % of Total Procurement, 2015• Revenue and Net Income of Surexam Biotechnology, 2015-2020E• Revenue and Net Income of Medicalsystem Biotechnology, 2011-2016• Revenue Breakdown of Medicalsystem Biotechnology by Product, 2011-2016• Gross Margin of Medicalsystem Biotechnology by Product, 2011-2016• R&D Costs and % of Total Revenue of Medicalsystem Biotechnology, 2011-2016• Projects Proposed/Under Construction of Medicalsystem Biotechnology• Revenue from and Gross Margin of Independent Clinical Laboratory Business of Medicalsystem Biotechnology, 2011-2016• Revenue of Medicalsystem Biotechnology’ Top 5 Clients and % in Total Revenue, 2011-2016• Procurement of Medicalsystem Biotechnology’ Top 5 Suppliers and % in Total Procurement, 2011-2016

Selected Charts


• Revenue and Net Income of Medicalsystem Biotechnology, 2015-2020E• Revenue and Net Income of Beijing Lawke, 2013-2016• Revenue Breakdown of Beijing Lawke by Region, 2014-2016• Gross Margin of Beijing Lawke by Business, 2013-2016• Revenue and Net Income of Beijing Lawke, 2015-2020E• Revenue and Net Income of Lepu Gene, 2013-2016• Gross Margin of Lepu Gene,2013-2016• Revenue and Net Income of Lepu Gene, 2015-2020E• Revenue and Net Income of Biotecan,2013-2016• Revenue Breakdown of Shanghai Biotecan by Business 2014-2016• Gross Margin of Shanghai Biotecan, 2014-2016• Clinical Laboratory Revenue of Shanghai Biotecan and % of Total Revenue, 2013-2016 • Revenue and Net Income of Biotecan, 2015-2020E• Revenue and Net Income of Jiangsu Superbio, 2014-2015• Revenue Breakdown of JiangsuSuperbio by Business,2014-2015• Revenue Breakdown of S Jiangsu Superbio by Region,2014-2015• Gross Margin of Jiangsu Superb by business,2014-2015• Revenue of Jiangsu Superb from Top 5 Clients and % of Total Revenue, 2014-2015• Procurement of Jiangsu Superb from Top 5 Suppliers and % of Total Procurement, 2014-2015• Revenue and Net Income of Jiangsu Superbio, 2015-2020• Milestones of Kindstar Global• Some Strategic Partners of ADINOVO• Chinese Independent Clinical Laboratory Market Size and YoY Growth, 2014-2020E• Revenue of Major Independent Clinical Laboratory Enterprises in China, 2011-2016• Clinical Laboratory Revenue of Major Enterprises in Independent Clinical Laboratory Industry in China, 2012-2016• Gross Margin of Major Enterprises in Independent Clinical Laboratory Industry in China, 2012-2016• Gross Margin of Clinical Laboratory Business of Major Independent Clinical Laboratory Enterprises in China, 2012-2016

Selected Charts


You can place your order in the following alternative ways:

1.Order online at www.researchinchina.com

2.Fax order sheet to us at fax number:+86 10 82601570

3. Email your order to: [email protected]

4. Phone us at +86 10 82600828/ 82601561

Party A:Name:Address:Contact Person: TelE-mail: Fax

Party B:Name: Beijing Waterwood Technologies Co., Ltd (ResearchInChina)Address: Room 509, Building 1+1, No.10, Caihefang Road, Haidian District, Beiji

ng, 100080 Contact Person:

Liao Yan Phone:

86-10-82600828

E-mail: [email protected] Fax: 86-10-82601570Bank details:

Beneficial Name: Beijing Waterwood Technologies Co., LtdBank Name: Bank of Communications, Beijing BranchBank Address: NO.1 jinxiyuan shijicheng,Landianchang,Haidian District,BeijingBank Account No #: 110060668012015061217Routing No # : 332906Bank SWIFT Code: COMMCNSHBJG

Title Format Cost

Total

Choose type of format

PDF (Single user license) …………..2,300 USD

Hard copy ………………….……. 2,500 USD

PDF (Enterprisewide license)…....... 3,700 USD

※ Reports will be dispatched immediately

once full payment has been received.

Payment may be made by wire transfer or

credit card via PayPal.

How to Buy


http://www.researchinchina.com/

mailto:[email protected]

About ResearchInChina

ResearchInChina (www.researchinchina.com) is a leading independent provider of China business

intelligence. Our research is designed to meet the diverse planning and information needs of businesses,

institutions, and professional investors worldwide. Our services are used in a variety of ways, including

strategic planning, product and sales forecasting, risk and sensitivity management, and as investment

research.

Our Major ActivitiesMulti-users market reportsDatabase-RICDBCustom ResearchCompany Search

For any problems, please contact our service team at:

Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● [email protected]

RICDB service

China independent clinical laboratory industry report, 2016 2020

Data & Analytics

Transcript of China independent clinical laboratory industry report, 2016 2020